
Keywords: AE; adverse event; AESI; adverse event of special interest; AMD; age-related macular degeneration; ANCHOR; Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-related macular degeneration; APTC; Antiplatelet T